Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 369-372

  Rytting, Michael ^a   Triche, Lisa ^a   Thomas, Deborah ^a   O'Brien, Susan ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; CD 22; CMC 544; Relapse

Indexed keywords

BILIRUBIN; CD22 ANTIGEN; INOTUZUMAB OZOGAMICIN; LIVER ENZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEVER; HUMAN; HYPOTENSION; INFANT; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOBLAST; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SEPSIS; THROMBOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 84890875516     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24721     Document Type: Article

References (17)

1. Chessells J, Veys P, Kempski H, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaema. Br J Haematol 2003; 123:396-405.
2. Uderzo C, Valsecchi MG, Bacigalupo A, et al. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: Ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995; 13:352-358.
3. Locatelli F, Schrappe M, Bernardo M, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012; 120:2807-2816.
4. Einsiedel H, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol 2005; 23:7942-7950.
5. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28:2339-2347.
6. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: A matched-pair analysis. Blood 2003; 101:3835-3839.
7. Gaynon PS, Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131:579-587.
8. Thomas D, Kantarjian H, Smith T, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86:1216-1230.
9. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113:3186-3191.
10. Boue D, LeBien T. Expression and structure of CD22 in acute leukemia. Blood 1988; 71:1480-1486.
11. Ricart A. Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17:6417-6427.
12. Ellestad G. Structural and conformational features relevant to the anti-tumor activity of calicheamicin gamma 1I. Chirality 2011; 23:660-671.
13. Ogura M, Hatake K, Ando K, et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012; 103:933-938.
14. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 2012; 13:403-411.
15. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99:2310-2314.
16. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31:599-604.
17. de Vries J, Zwaan C, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012; 26:255-264.